{
    "id": 17328,
    "fullName": "ATM del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ATM del indicates a deletion of the ATM gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 472,
        "geneSymbol": "ATM",
        "terms": [
            "ATM",
            "AT1",
            "ATA",
            "ATC",
            "ATD",
            "ATDC",
            "ATE",
            "TEL1",
            "TELO1"
        ]
    },
    "variant": "del",
    "createDate": "01/29/2016",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19477,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment induced genomic instability, cell cycle arrest, and inhibited viability of an ATM knockout head and neck cancer cell line in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19478,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment increased sensitivity to Lynparza (olaparib), inducing cell cycle arrest and inhibiting viability of ATM knockout non-small cell lung carcinoma cells in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19475,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment increased sensitivity to Lynparza (olaparib), resulting in inhibition of Dna-pk phosphorylation, reduced cell viability, genomic instability, cell cycle arrest, and apoptosis in a head and neck cancer cell line with ATM deletion in culture, and inhibition of tumor growth and complete tumor regression in a cell line xenograft model (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment inhibited viability of ATM knockout non-small cell lung carcinoma cells in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19476,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment induced genomic instability, cell cycle arrest, and inhibited viability of an ATM knockout head and neck cancer cell line in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 11934,
                "name": "head and neck cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited viability of ATM knockout non-small cell lung carcinoma cells in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 17614,
                "profileName": "ATM del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ATM-null transformed cells with decreased Atr expression demonstrated decreased sensitivity to PJ34 in culture (PMID: 21840268).",
            "molecularProfile": {
                "id": 27811,
                "profileName": "ATM del ATR dec exp"
            },
            "therapy": {
                "id": 2541,
                "therapyName": "PJ34",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8869,
                    "pubMedId": 21840268,
                    "title": "The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21840268"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11387,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",
            "molecularProfile": {
                "id": 27978,
                "profileName": "ATM del KRAS G12D"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9282,
                    "pubMedId": 28363999,
                    "title": "ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363999"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11388,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999).",
            "molecularProfile": {
                "id": 27978,
                "profileName": "ATM del KRAS G12D"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9282,
                    "pubMedId": 28363999,
                    "title": "ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363999"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17614,
            "profileName": "ATM del",
            "profileTreatmentApproaches": [
                {
                    "id": 7899,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "ATM del"
                }
            ]
        },
        {
            "id": 27811,
            "profileName": "ATM del ATR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27978,
            "profileName": "ATM del KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}